NPI 1891825733: Open Payments
NPI 1891825733. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 52 payments from 16 companies in 2025. Trend: 2023 $995 · 2024 $1,060 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $175 |
| ABBVIE INC. | 13 | $141 |
| Novartis Pharmaceuticals Corporation | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Verona Pharma, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| PFIZER INC. | 1 | $18 |
Products named: VRAYLAR, EVENITY, LEQVIO, CAPLYTA, OTEZLA, Ohtuvayre, Veozah, Auvelity.
